📊 ELAB Key Takeaways
Is PMGC Holdings Inc. (ELAB) a Good Investment?
PMGC Holdings demonstrates fundamentally broken economics with only $682K in quarterly revenue against $7.7M in operating losses, indicating a pre-commercial or failed commercial product. Despite adequate near-term liquidity, the company is burning $3M+ in quarterly operating cash flow with an unsustainable cost structure and no clear path to profitability.
PMGC Holdings shows early top-line growth, but the quality of that growth is weak given revenue remains very small relative to a multi-million-dollar operating loss and deeply negative free cash flow. The balance sheet is supported by cash and no long-term debt, but current fundamentals indicate an unproven business model with substantial ongoing cash burn and poor operating efficiency.
PMGC Holdings Inc. Key Strengths (ELAB)
- No material debt with 0.00x debt/equity ratio provides financial flexibility
- Adequate liquidity with $14.4M cash and 1.45x current ratio for near-term survival
- Positive gross margin of 33.8% shows underlying product has reasonable unit economics
- Revenue grew 123.5% year over year, indicating some commercial traction from a low base
- Cash of $7.70M and current ratio of 1.79x provide near-term liquidity support
- No meaningful long-term debt reduces balance-sheet leverage risk
ELAB Stock Risks: PMGC Holdings Inc. Investment Risks
- Critically low revenue of $682K suggests failed commercialization or pre-revenue stage for a pharmaceutical company
- Operating expenses are 11x revenue generating $7.7M quarterly operating losses and -1136.3% operating margin
- Negative operating cash flow of $3M quarterly will deplete cash reserves in 4-5 years without dramatic operational improvement
- Operating margin of -1543.7% and net margin of -1666.4% show severe structural unprofitability
- Free cash flow of -$4.28M and negative operating cash flow of -$4.18M imply continued cash burn
- Revenue base of just $285.95K is far too small to support the current expense structure
Key Metrics to Watch
- Quarterly revenue trend and product sales breakdown by indication
- Monthly operating cash burn rate and cash runway extension
- FDA approvals, pipeline updates, and commercial execution metrics
- Quarterly revenue growth relative to operating expense growth
- Cash runway, including operating cash burn and ending cash balance
PMGC Holdings Inc. (ELAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
PMGC Holdings Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ELAB Profit Margin, ROE & Profitability Analysis
ELAB vs Healthcare Sector: How PMGC Holdings Inc. Compares
How PMGC Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PMGC Holdings Inc. Stock Overvalued? ELAB Valuation Analysis 2026
Based on fundamental analysis, PMGC Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PMGC Holdings Inc. Balance Sheet: ELAB Debt, Cash & Liquidity
ELAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PMGC Holdings Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.19 indicates the company is currently unprofitable.
ELAB Revenue Growth, EPS Growth & YoY Performance
ELAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $682.0K | -$1.6M | $-11.22 |
| Q3 2025 | $285.9K | -$1.5M | $-4.95 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PMGC Holdings Inc. Dividends, Buybacks & Capital Allocation
ELAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PMGC Holdings Inc. (CIK: 0001840563)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELAB
What is the AI rating for ELAB?
PMGC Holdings Inc. (ELAB) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELAB's key strengths?
Claude: No material debt with 0.00x debt/equity ratio provides financial flexibility. Adequate liquidity with $14.4M cash and 1.45x current ratio for near-term survival. ChatGPT: Revenue grew 123.5% year over year, indicating some commercial traction from a low base. Cash of $7.70M and current ratio of 1.79x provide near-term liquidity support.
What are the risks of investing in ELAB?
Claude: Critically low revenue of $682K suggests failed commercialization or pre-revenue stage for a pharmaceutical company. Operating expenses are 11x revenue generating $7.7M quarterly operating losses and -1136.3% operating margin. ChatGPT: Operating margin of -1543.7% and net margin of -1666.4% show severe structural unprofitability. Free cash flow of -$4.28M and negative operating cash flow of -$4.18M imply continued cash burn.
What is ELAB's revenue and growth?
PMGC Holdings Inc. reported revenue of $682.0K.
Does ELAB pay dividends?
PMGC Holdings Inc. does not currently pay dividends.
Where can I find ELAB SEC filings?
Official SEC filings for PMGC Holdings Inc. (CIK: 0001840563) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELAB's EPS?
PMGC Holdings Inc. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ELAB's fundamental grade?
Based on our AI fundamental analysis in June 2026, PMGC Holdings Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ELAB stock overvalued or undervalued?
Valuation metrics for ELAB: ROE of -39.4% (sector avg: 15%), net margin of -728.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ELAB's AI grade for 2026?
Our dual AI analysis gives PMGC Holdings Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELAB's free cash flow?
PMGC Holdings Inc.'s operating cash flow is $-3.0M, with capital expenditures of $363.1K. FCF margin is -490.1%.
How does ELAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -728.3% (avg: 12%), ROE -39.4% (avg: 15%), current ratio 1.45 (avg: 2).